Significant, defined as a greater than 50 percent narrowing, left main coronary artery disease is found in 4 to 6 percent of all patients who undergo coronary arteriography. When present, it is associated with multivessel coronary artery disease about 70 percent of the time
Coronary artery bypass grafting with adjunctive
endarterectomy: A mandatory procedure in complex
revascularizations. current results and postoperative
considerations
CTO PCI and length of dual antiplatelet regimenEuro CTO Club
CTO PCI and length of dual antiplatelet regimen
Maciej Lesiak, Poznan, Poland
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
An Overview of Filter-Protected Carotid Artery Stentinggailms
These slides give an overview of cerebral protection devices used today in carotid artery stenting, with special emphasis on distal protection filters. Previous work in the field, results from our laboratory, and future directions of device development are covered.
Significant, defined as a greater than 50 percent narrowing, left main coronary artery disease is found in 4 to 6 percent of all patients who undergo coronary arteriography. When present, it is associated with multivessel coronary artery disease about 70 percent of the time
Coronary artery bypass grafting with adjunctive
endarterectomy: A mandatory procedure in complex
revascularizations. current results and postoperative
considerations
CTO PCI and length of dual antiplatelet regimenEuro CTO Club
CTO PCI and length of dual antiplatelet regimen
Maciej Lesiak, Poznan, Poland
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
An Overview of Filter-Protected Carotid Artery Stentinggailms
These slides give an overview of cerebral protection devices used today in carotid artery stenting, with special emphasis on distal protection filters. Previous work in the field, results from our laboratory, and future directions of device development are covered.
Percutaneous Coronary Intervention [PCI] has been a revolutionary advance in cardiology, and many lives have been saved as a result of the widespread application of primary PCI. However, elective PCI has not yet been proven to save lives or reduce the risk of myocardial infarction. Despite this lack of
evidence, elective PCI has been misused and in some cases, abused for nonmedical reasons. The considerable cost of elective PCI can be reduced, and the resources could potentially be utilized for better public health outcomes. The following.article intends to highlight the lack of evidence supporting the use of elective PCI, which is a problem not only in North America and Europe but also throughout the world.
Better regulation of the elective PCI procedure could reduce health care expenditures and divert resources to cardiovascular disease prevention.
What is New in Cardiac CT? In Search of the Comprehensive and Conclusive Hear...Apollo Hospitals
Coronary CT Angiography (CT) with its noninvasive cross sectional information has seen remarkable growth in recent years. With the introduction of the new generation scanners, like the 320-slice CT, it has risen to a whole new level. Percent diameter stenosis determined with the use of 320-slice CT shows good correlation with Invasive catheter angiogram (ICA) without significant underestimation or overestimation. Plaque composition on CT regardless of lesion severity has emerged as a strong predictor of major cardiac events. The percentage stenosis mismatch between CT and ICA can be explained by the 2 dimensional nature of ICA and its interpretive inconsistencies. In the upcoming years, we need to evolve from focusing on lumen stenosis to a comprehensive assessment of CAD and its impact on patient outcome.
Coronary endarterectomy and patch angioplasty for diffuse coronary artery dis...Abdulsalam Taha
CABG may not be sufficient to treat the diffusely diseased coronary arteries. New techniques such as coronary endarterectomy with patch angioplasty may provide a solution.
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...Premier Publishers
Coronary tortuosity is a common angiographic finding. This study was done to observe the clinical profile of patients with coronary tortuosity (CT) and its relation with coronary artery disease (CAD). Method: A total 224 patients undergoing angiography for suspected CAD were included in the study. Coronary tortuosity was defined by the presence of ≥3 consecutive bends of > 45 degree, measured at end-diastole in an epicardial artery ≥2 mm in diameter. Coronary tortuosity was present in 45(20.1%) patients (CT group) in the study and another 45 patients without coronary tortuosity was randomly selected as control (NCT group). Clinical profile of CT and NCT group was compared. Results: Incidence of coronary tortuosity was significantly higher in females (p=0.000) and hypertensives (p=0.001) patients. Coronary tortuosity was most commonly seen in Left circumflex coronary artery. Incidence of CAD was significantly lower in CT group as compare to NCT group (0.02). Risk factors for CAD was associated with reduced incidence of Coronary tortuosity. Majority (88.5%) patient with CT without CAD presented with chronic stable angina out of which (65.2%) had an objective evidence of myocardial ischemia. Conclusion: Coronary tortuosity is more commonly seen females and hypertensive patients. It has negative correlation with CAD but can lead to myocardial ischemia. Risk factors of CAD do not predict CT.
postgraduate education for cardiothoracic anaesthesia and intensive care doctors in cardiac operations on patients with unstable ischemic heart disease
15th Experts Live CTO - Carlo Di Mario: ConclusionsEuro CTO Club
PLENARY SESSION
Wrap up of live cases, awards to the winners of the best abstracts and case competitions and take home messages
Auditorium Zubin Mehta - Saturday 16:00 - 17:00
Speakers:
Daniela Benedetto (Rome),
Francesco Burzotta (Rome),
Carlo Di Mario (Florence),
Roberto Garbo (Turin),
Rocco Stio (Rome)
Challengers:
Stelios Pyxaras (Furth - D),
Sudhir Rathore (London - UK)
Discussants:
Shunsuke Matsuno (Tokyo - J),
Alexander Nap (Amsterdam - NL),
Masahisa Yamane (Tokyo - J)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Francesco Burzotta: Wrap up Gemelli CasesEuro CTO Club
PLENARY SESSION
Wrap up of live cases, awards to the winners of the best abstracts and case competitions and take home messages
Auditorium Zubin Mehta - Saturday 16:00 - 17:00
Speakers:
Daniela Benedetto (Rome),
Francesco Burzotta (Rome),
Carlo Di Mario (Florence),
Roberto Garbo (Turin),
Rocco Stio (Rome)
Challengers:
Stelios Pyxaras (Furth - D),
Sudhir Rathore (London - UK)
Discussants:
Shunsuke Matsuno (Tokyo - J),
Alexander Nap (Amsterdam - NL),
Masahisa Yamane (Tokyo - J)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Jonathan Hill: Role of mechanica support in CTO recanalizationEuro CTO Club
10:42
Role of mechanica support in CTO recanalization
Jonathan Hill (London - UK)
___________________________________________
PARALLEL SESSION
Challenges And Opportunities In Cto Recanalization
Auditorium Zubin Mehta - Saturday 10:00 - 11:10
Chairperson:
Jonathan Hill (London - UK)
Discussants:
Lesnek Bryniarski (Krakow - PL),
Ugo Fabrizio (Vercelli),
Paul Knaapen (Amsterdam - NL),
Eugenio La Scala (Ollioiouls - F)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Gregor Leibundgut: Role of DEB in CTO-PCIEuro CTO Club
10:35 Role of DEB in CTO-PCI
Gregor Leibundgut (Basel - CH)
___________________________________________
PARALLEL SESSION
Challenges And Opportunities In Cto Recanalization
Auditorium Zubin Mehta - Saturday 10:00 - 11:10
Chairperson:
Jonathan Hill (London - UK)
Discussants:
Lesnek Bryniarski (Krakow - PL),
Ugo Fabrizio (Vercelli),
Paul Knaapen (Amsterdam - NL),
Eugenio La Scala (Ollioiouls - F)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Kambis Mashayekhi: EuroCTO Consensus on treatment of Calcified CTO lesion Eur...Euro CTO Club
AUDITORIUM ZUBIN MEHTA
08/09/2023 04:30 - 05:20
PLENARY SESSION - INTERVENTIONAL CTO & CHIP RESEARCH Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...Euro CTO Club
16:53
CTO PCI Outcome associated with poor quality of the distal target vessel
Emmanouil Brilakis (Minneapolis - USA)
_____________________________________________
PARALLEL SESSION
Interventional CTO & Chip Research
Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Auditorium Zubin Mehta - Friday 16:30 - 17:16
Chairpersons:
Davide Capodanno (Catania),
Carlo Di Mario (Florence),
Giuseppe Tarantini (Padua)
Panelist:
Roberto Diletti (Rotterdam - NL),
Giovanni Esposito (Naples),
Paul Knaapen (Amsterdam - NL),
Maksymilian Opolski (Warsaw - PL)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Mario Iannaccone - 2 EuroCTO Consensus on Guide Catheter Extensions JACC Card...Euro CTO Club
16:33
EuroCTO Consensus on Guide Catheter Extensions JACC Cardiovasc Interventions
Mario Iannaccone (Turin)
_____________________________________________
PARALLEL SESSION
Interventional CTO & Chip Research
Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Auditorium Zubin Mehta - Friday 16:30 - 17:16
Chairpersons:
Davide Capodanno (Catania),
Carlo Di Mario (Florence),
Giuseppe Tarantini (Padua)
Panelist:
Roberto Diletti (Rotterdam - NL),
Giovanni Esposito (Naples),
Paul Knaapen (Amsterdam - NL),
Maksymilian Opolski (Warsaw - PL)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
1. CBFKARDIOLOGIE
U. Landmesser
Chairman, Department of Cardiology (CBF); BIH Professor of Cardiology;
Chair – Cardiovascular Center
Charité – Universitätsmedizin Berlin
16.9.2017 Berlin – EUROCTO CLUB
What Future Trials Do We
Need in CTOs ?
2. CBFKARDIOLOGIE
1) CTO and Coronary Revascularisation
in Stable CAD and Prognosis ?
1) CTO Revascularisation and
Symptomatic Improvement
2) Further Improvement in CTO Outcomes
– IC Imaging ?
What Future Trials Do We
Need in CTOs ?
3. CBFKARDIOLOGIE
Eur Heart J. 2014 Aug 29. pii: ehu278. [Epub ahead of print]
European Guideline for Treatment of CAD:
ESC/EACTS Guidelines on Myocardial revascularisation
4. CBFKARDIOLOGIE
The indications for revascularization in patients with SCAD are
persistence of symptoms despite medical treatment and/or
improvement of prognosis
Indications for revascularization in patients with stable
angina or silent ischemia
Eur Heart J. 2014 Aug 29. pii: ehu278. [Epub ahead of print]
5. CBFKARDIOLOGIE
Impact of ischaemia on therapeutic benefit derived from
myocardial revascularisation vs. medical therapy
Modeling revealed > 10 % total myocardium associated with a survival benefit
13 555 patients; 7 year FU for All cause mortality
Hachamovitch et al.; European Heart Journal (2011) 32, 1012–1024
8. CBFKARDIOLOGIE
CTO Revascularisation and Cardiovascular
Outcome in Randomized Trials
Di Mario C, Sorini Dini C, Werner GS. JACC Cardiovasc Interv. 2017 Aug 14;10(15):1535-1537
9. CBFKARDIOLOGIE
CTO associated with increased Recurrence of
Ventricular Arrhythmias in Ischemic Cardiomyopathy
JACC Cardiovasc Interv. 2017 May 8;10(9):879-888.
10. CBFKARDIOLOGIE
JACC Cardiovasc Interv. 2017 May 8;10(9):879-888.
CTO associated with increased Recurrence of
Ventricular Arrhythmias in Ischemic Cardiomyopathy
12. CBFKARDIOLOGIE
N Engl J Med. 2016 Apr 21;374(16):1511-20
Revascularisation in ischemic
cardiomyopathy:STICHES Trial
Coronary disease and
LV-EF ≤35%
13. CBFKARDIOLOGIE
This STICH Extension Study (STICHES):
•15-year effort, achieving a 98% rate of follow-up
of 1212 patients with heart failure and severe left
ventricular dysfunction
•Randomly assigned to receive either medical
therapy alone or medical therapy plus coronary-
artery bypass grafting (CABG).
N Engl J Med. 2016 Apr 21;374(16):1511-20
vascularisation in ischemic cardiomyopath
STICH Extension Study
(STICHES)
16. CBFKARDIOLOGIE
Hazard ratio (solid line) and 95% confidence interval (CI; gray area) for the effect of
coronary artery bypass grafting vs medical therapy across the range of ages.
Age and Ten-Year Outcomes After CABG – STICHES Study
in Patients With Heart Failure and Left Ventricular Systolic
DysfunctionClinical Perspective
Mark C. Petrie et al.
Circulation. 2016;134:1314-1324
17. CBFKARDIOLOGIE
- 1) Large area of ischemia
- 2) Impaired LV Function
- 3) Younger patients ?
- 4) Long-term Follow-Up
will be needed
In which patients one may expect a potential
prognostic benefit from CTO recanalisation
18. CBFKARDIOLOGIE
1) CTO and Coronary Revascularisation
in Stable CAD and Prognosis ?
1) CTO Revascularisation and
Symptomatic Improvement
2) Further Improvement in CTO Outcomes
– IC Imaging ?
What Future Trials Do We
Need in CTOs ?
19. CBFKARDIOLOGIE
OPEN CTO Registry; JACC Cardiovasc Interv. 2017 Aug 14;10(15):1523-1534
CTO Indications: OPEN-CTO Registry
All operators enrolling in OPEN-CTO trial received training in hybrid
approach and had performed over 100 cases using this method.
22. CBFKARDIOLOGIE
1) CTO and Coronary Revascularisation
in Stable CAD and Prognosis ?
1) CTO Revascularisation and
Symptomatic Improvement
2) Further Improvement in CTO Outcomes
– IC Imaging ?
What Future Trials Do We
Need in CTOs ?
23. CBFKARDIOLOGIE
IVUS-Guided PCI (using DES) and
impact on clinical outcomes
- Included 7 randomized trials
with 3192 patients.
- This meta-analysis suggests
that for complex coronary
lesions (mean length coronary
lesions: 32 mm) IVUS-guided
PCI was superior to
angiography-guided PCI in
reducing the risk of MACE
(primarily: reduction in the risk
of ischemia-driven target lesion
revascularization).
Elgendy et al.: Circ Cardiovasc Interv. 2016; 9: e003700
24. CBFKARDIOLOGIE
ILUMIEN IV Study:
Prognostic impact of OCT-guided Coronary Intervention
Pre-PCI OCT Angiography
OCT Stent Sizing Guidance, per
study protocol
OCT guided Optimization per
study protocol
Angiography guided PCI, per
“local standard practice”
Angiographic optimization, per
“local standard practice”
Post-PCI OCT
Angiography
Randomization to OCT or
angiography- guided PCI
Identification of study lesion
Procedure Complete
Post-PCI OCT, blinded to
investigator
1-year follow-up
Inclusion
High-risk clinical characteristics
•Medically treated DM, or
•Troponin positive ACS w/in 7 days,
OR
Complex-target lesion
•Long or multiple lesions
(stent length ≥ 28mm), or
•Bifurcation with 2 planned stents, or
•Angiographic severe Ca2+
, or
•CTO (crossed and pre-dilated) , or
•Diffuse or multi-focal in-stent restenosis
25. CBFKARDIOLOGIE
1) CTO and Coronary Revascularisation
in Stable CAD and Prognosis ?
1) CTO Revascularisation and
Symptomatic Improvement
2) Further Improvement in CTO Outcomes
– IC Imaging ?
What Future Trials Do We
Need in CTOs ?
Hazard ratio (solid line) and 95% confidence interval (CI; gray area) for the effect of coronary artery bypass grafting vs medical therapy across the range of ages.